OncoCyte Corporation (OCX) Bundle
A Brief History of OncoCyte Corporation (OCX)
Formation and Early Years
Formation and Early Years
OncoCyte Corporation was established in 2014 as a spin-off from BioTime, Inc. The company focused on the development of innovative cancer diagnostics aimed at improving treatment decisions for patients. The organization initially specialized in liquid biopsy technologies and the commercialization of non-invasive tests.
Key Developments in Product Pipeline
OncoCyte's flagship product, DetermaRx, a test for lung cancer patients, was launched in November 2020. The test aims to determine the likelihood of recurrence in early-stage lung cancer and assists physicians in tailoring treatment decisions.
Acquisitions and Collaborations
In April 2021, OncoCyte announced the acquisition of RazorGen, a molecular diagnostics company. This acquisition was part of a broader initiative to enhance its diagnostic portfolio. The partnership aimed to leverage RazorGen's expertise in liquid biopsy technology.
Financial Performance Overview
As of the second quarter of 2023, OncoCyte reported revenue of approximately $1.34 million, marking a year-over-year increase from $0.89 million in Q2 2022. The total revenue for the fiscal year 2022 was $4.6 million.
| Financial Indicator | Q2 2022 (in millions) | Q2 2023 (in millions) | Fiscal Year 2022 (in millions) |
|---|---|---|---|
| Revenue | 0.89 | 1.34 | 4.6 |
| Net Loss | (5.1) | (3.9) | (18.5) |
| Cash and Cash Equivalents | 12.3 | 9.5 | 10.2 |
| Market Capitalization | 145.2 | 92.3 | N/A |
Clinical Trials and Research Initiatives
OncoCyte has engaged in several clinical trials to validate its products. The company reported the successful completion of a clinical study involving DetermaRx, which demonstrated the test's effectiveness in predicting recurrence.
Recent Corporate Strategy and Outlook
In 2023, OncoCyte announced a strategic focus on expanding its commercial operations, aiming to increase market penetration for DetermaRx and future diagnostic tests. The company plans to utilize its existing technology platforms to develop new diagnostic solutions in oncology.
Challenges and Market Conditions
Despite its advancements, OncoCyte faces challenges such as increased competition in the liquid biopsy market and regulatory hurdles. As of August 2023, the company's stock price was approximately $1.09, reflecting the volatility of the biotech sector.
Investment and Funding
OncoCyte has raised significant capital through various financing rounds. In early 2022, the company secured $15 million in a private placement to support its operational needs and research initiatives.
| Funding Round | Date | Amount Raised (in millions) |
|---|---|---|
| Private Placement | January 2022 | 15 |
| Public Offering | October 2021 | 10 |
| Series A | June 2014 | 5 |
Conclusion of Developments
OncoCyte Corporation remains focused on its mission to revolutionize cancer diagnostics. The company continues to seek innovative opportunities to enhance patient care through its advanced testing solutions.
A Who Owns OncoCyte Corporation (OCX)
Major Shareholders
As of the latest available data, the ownership structure of OncoCyte Corporation (OCX) comprises institutional investors, retail investors, and corporate insiders. Below is a detailed breakdown of major shareholders:
| Shareholder Type | Name | Ownership Percentage | Shares Owned |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 10.2% | 6,300,000 |
| Institutional Investor | RTW Investments, LP | 9.5% | 5,500,000 |
| Institutional Investor | Vanguard Group, Inc. | 8.0% | 4,800,000 |
| Corporate Insider | Ronald A. Cohen, Ph.D. | 3.5% | 2,100,000 |
| Retail Investor | Public Float | 68.8% | 41,000,000 |
Recent Stock Performance
As of October 2023, OncoCyte Corporation (OCX) has experienced fluctuations in stock performance. The following table highlights key financial metrics:
| Date | Closing Price | Market Capitalization | Volume |
|---|---|---|---|
| October 2, 2023 | $1.75 | $110 million | 1,200,000 |
| October 9, 2023 | $1.85 | $115 million | 900,000 |
| October 16, 2023 | $1.90 | $117 million | 1,100,000 |
| October 23, 2023 | $1.80 | $113 million | 800,000 |
| October 30, 2023 | $2.00 | $120 million | 1,300,000 |
Investment by Insiders
Insider transactions have also played a role in the ownership landscape of OncoCyte Corporation. The following summarizes recent insider activities:
| Insider | Transaction Type | Date | Shares Traded |
|---|---|---|---|
| Ronald A. Cohen, Ph.D. | Buy | September 15, 2023 | 250,000 |
| Lisa M. McEwen | Sell | August 20, 2023 | 150,000 |
| James A. Holland | Buy | July 10, 2023 | 100,000 |
| Ronald A. Cohen, Ph.D. | Sell | June 5, 2023 | 75,000 |
| Lisa M. McEwen | Buy | May 8, 2023 | 200,000 |
Shareholder Meetings
OncoCyte Corporation conducts regular shareholder meetings. Key points from the latest meeting held in April 2023 are documented below:
| Agenda Item | Outcome |
|---|---|
| Approval of Annual Financials | Passed |
| Election of Board Members | Passed |
| Issuance of Stock Options | Rejected |
| Increase Shareholder Return Policy | Passed |
OncoCyte Corporation (OCX) Mission Statement
OncoCyte Corporation, a biotechnology company, focuses on the development and commercialization of novel diagnostic tests to improve cancer detection and treatment. Their mission statement emphasizes the commitment to delivering innovative solutions that enhance patient outcomes through early detection and personalized care.
Core Values
- Integrity - Conducting business with transparency and ethics.
- Innovation - Continuously striving to enhance diagnostic capabilities.
- Patient-Centricity - Prioritizing patient care and well-being in all initiatives.
- Collaboration - Engaging with stakeholders for better health solutions.
Strategic Goals
OncoCyte aims to achieve several strategic objectives:
- Develop and commercialize advanced diagnostic tests.
- Expand market presence and accessibility of oncology diagnostics.
- Foster partnerships with healthcare providers and research institutions.
- Increase awareness and usage of non-invasive cancer testing.
Recent Financial Performance
| Year | Revenue (in millions) | Net Income (in millions) | Total Assets (in millions) | Market Capitalization (as of October 2023, in millions) |
|---|---|---|---|---|
| 2022 | $8.45 | -$22.65 | $35.30 | $83.14 |
| 2021 | $6.25 | -$18.70 | $30.75 | $60.50 |
| 2020 | $5.10 | -$15.20 | $28.00 | $45.80 |
Key Products and Services
OncoCyte's product portfolio includes:
- DetermaRx - A test designed to predict the risk of lung cancer recurrence.
- DetermaCyt - A diagnostic platform focused on early detection of cancer.
- Research and Development Services - Offering collaboration opportunities for biomarker development.
Market Trends and Position
OncoCyte operates within a growing oncology diagnostics market, which was valued at approximately $17.4 billion in 2022 and is expected to reach $29.3 billion by 2030, growing at a CAGR of 6.8%.
Recent Developments
As of October 2023, OncoCyte launched a new marketing campaign to raise awareness about its diagnostic tests, targeting an estimated 40% increase in customer engagement by mid-2024.
Partnerships and Collaborations
OncoCyte has established partnerships with several institutions:
- University of California, San Francisco (UCSF) - Collaborative research on lung cancer diagnostics.
- The Mayo Clinic - Joint efforts in developing new testing methodologies.
- Genomic Health - Working on integrating genomic profiling into diagnostic tests.
Future Outlook
The company projects a revenue growth of 20% annually over the next five years, with aspirations to launch additional products that enhance early cancer detection capabilities.
How OncoCyte Corporation (OCX) Works
Business Model
Business Model
OncoCyte Corporation operates in the field of cancer diagnostics, focusing on the development and commercialization of proprietary tests to enable earlier detection of cancer. The company’s primary products utilize its expertise in molecular biology and bioinformatics.
Key Products
- DetermaRx: A test designed for patients with early-stage lung cancer to inform decisions regarding adjuvant chemotherapy.
- DetermaIO: A test aimed at predicting response to immune checkpoint inhibitors in cancer patients.
Market Position
As of Q3 2023, OncoCyte’s market capitalization stood at approximately $66 million. The company aims to capture a share of the expanding cancer diagnostics market, projected to reach nearly $200 billion by 2027.
Financial Overview
| Financial Metric | Q3 2023 Value | Q2 2023 Value | Change (%) |
|---|---|---|---|
| Revenue | $2.5 million | $2.1 million | 19% increase |
| Net Loss | ($3.8 million) | ($4.1 million) | 7% decrease |
| Cash and Equivalents | $15.7 million | $16.2 million | -3% decrease |
Research and Development Spending
In 2023, OncoCyte allocated approximately $4.5 million for research and development, focusing on enhancing the performance of its diagnostic assays. This investment accounts for around 40% of the total expenses.
Strategic Collaborations
- Collaboration with Biodesix: A partnership that leverages respective technologies to advance lung cancer diagnostics.
- Partnership with major healthcare providers: To facilitate clinical adoption of OncoCyte's tests.
Regulatory Compliance
OncoCyte's tests are designed to comply with FDA regulations and are marketed as laboratory-developed tests (LDTs). The company continues to engage with regulatory bodies to ensure compliance and validation of its products.
Future Outlook
OncoCyte anticipates growth driven by increasing awareness of early cancer detection methods and the expansion of its test offerings. In 2024, the company projects a revenue target of $10 million, driven by additional test launches and partnerships.
How OncoCyte Corporation (OCX) Makes Money
Revenue Streams
OncoCyte Corporation generates revenue primarily through its innovative diagnostic tests. The company focuses on developing and commercializing liquid biopsy tests that assist in the early detection of cancer. In 2022, OncoCyte reported total revenues of approximately $5.1 million, a significant increase from $3.4 million in 2021.
Product Offerings
OncoCyte's key product is the DetermaRx test, which helps clinicians identify patients with lung cancer who are at high risk of recurrence. The pricing for DetermaRx is typically around $3,500 per test. The following table summarizes the details of OncoCyte's principal products and their associated revenues:
| Product | Year Launched | Average Price per Test | 2022 Revenue |
|---|---|---|---|
| DetermaRx | 2019 | $3,500 | $4.0 million |
| DetermaIO | 2021 | $3,800 | $1.1 million |
Partnerships and Collaborations
OncoCyte engages in strategic partnerships to enhance its market reach and product offerings. For instance, the collaboration with Fulgent Genetics aims to expand the accessibility of DetermaRx. This partnership has been projected to generate an additional $2 million in revenue by the end of 2023.
Market Potential
The market for liquid biopsy tests is rapidly expanding. In 2021, the global liquid biopsy market was valued at approximately $4 billion, and it is projected to reach $9.3 billion by 2026, growing at a CAGR of 16%. This substantial growth indicates a favorable market environment for OncoCyte's products.
Expenditure and Investment
In 2022, OncoCyte's total operating expenses amounted to approximately $20 million. The breakdown of these expenses is shown in the following table:
| Expense Category | Amount (2022) |
|---|---|
| Research and Development | $10 million |
| Sales and Marketing | $6 million |
| General and Administrative | $4 million |
Funding and Financial Position
OncoCyte has raised funds through various financing rounds. In 2021, the company secured a gross amount of $26 million in a public offering. As of the latest reports, OncoCyte has cash and cash equivalents amounting to $18 million, sufficient to support its operations for the next 12-18 months.
Future Outlook
OncoCyte aims to launch additional tests and expand its footprint within the oncology market. The introduction of new products is expected by 2024, and revenue from these new offerings could contribute an estimated $7 million to total company revenues.
OncoCyte Corporation (OCX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support